financetom
Business
financetom
/
Business
/
Slowing Hoka Brand Growth Drive Deckers Outdoor Downgrade at KeyBanc Amid Demand Concerns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Slowing Hoka Brand Growth Drive Deckers Outdoor Downgrade at KeyBanc Amid Demand Concerns
May 26, 2025 1:26 PM

11:24 AM EDT, 05/23/2025 (MT Newswires) -- Deckers Outdoor's ( DECK ) strong fiscal fourth-quarter results were overshadowed by sales growth deceleration at its Hoka sneaker brand and potential demand weakness from price increases, prompting KeyBanc Capital Markets to downgrade the footwear and apparel company's stock.

The company late Thursday reported earnings of $1 a share for the March quarter, up from $0.82 the year before, while sales rose 6.5% to $1.02 billion. Both metrics topped market expectations.

Within its brands, Hoka recorded revenue of $586.1 million, representing a year-over-year gain of 10%. However, Hoka's annual pace of growth has slowed down since the second quarter of the company's fiscal 2025, according to the KeyBanc report emailed Friday.

"Hoka quarter sales were slightly below our expectations, and growth into (the first quarter) marks a clear deceleration within the brand, as headwinds like slower customer acquisition and macro pressure materialize," according to the brokerage. "The Hoka brand no longer feels as competitively positioned (versus) other disruptive running brands that continue to outperform, raising concerns it may be losing mindshare."

KeyBanc lowered its rating on Deckers' stock to sector weight from overweight. Shares of the company sank 20% in Friday trade.

Deckers continues to assess actions to offset impacts from changes to tariff policies, "including, but not limited to, flexing the pricing power of our brands," Chief Financial Officer Steve Fasching said during a Thursday earnings call with analysts, according to a FactSet transcript.

"Although, even with these mitigation efforts, we expect to absorb a portion of the tariff impact, as we do not anticipate that these actions will fully offset incremental costs in fiscal year 2026," Fasching told analysts. "We also believe there is potential to see demand erosion associated with the combination of price increases and general softness in the consumer spending environment."

US President Donald Trump on Friday recommended a 50% tariff rate on the European Union, effective June 1, saying that trade discussions with the bloc were "going nowhere."

After announcing sweeping new import tariffs in early April, Trump declared a 90-day pause on certain duties for non-retaliating countries. Recently, the US and China agreed to suspend most levies on each other's goods for 90 days, while Washington reached a trade deal with the UK.

For the ongoing quarter, Deckers expects EPS of $0.62 to $0.67 and sales between $890 million and $910 million. The current consensus on FactSet is for GAAP EPS of $0.68 and sales of $901.5 million.

KeyBanc slashed its first-quarter EPS estimate to $0.65 from $0.81 for Deckers, while seeing revenue at $893.5 million, down from $934.6 million previously expected.

"Given the macroeconomic uncertainty related to evolving global trade policies, the company will not be providing full year guidance for fiscal year 2026 at this time," Deckers said on Thursday.

Price: 99.90, Change: -26.19, Percent Change: -20.77

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing
Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing
May 26, 2025
08:33 AM EDT, 05/14/2025 (MT Newswires) -- Quoin Pharmaceuticals ( QNRX ) said Wednesday preliminary results from a study evaluating its therapy candidate QRX003 in a pediatric peeling skin syndrome patient showed 'clear evidence of skin healing' in the area treated over 12 weeks. The company reported progress across multiple endpoints, including that QRX003 has been well tolerated with no...
Sernova Biotherapeutics Provides
Sernova Biotherapeutics Provides "Positive" Interim Data From Type 1 Diabetes Cell Pouch Trial
May 26, 2025
08:33 AM EDT, 05/14/2025 (MT Newswires) -- Sernova Biotherapeutics ( SEOVF ) on Wednesday said interim data from its ongoing Phase 1/2 clinical trial in patients with type 1 diabetes (T1D) show a majority of the enrolled patients achieving insulin independence and improved blood sugar control. The clinical trial involved transplanting Sernova's cell pouch with human donor cells or stem-cell...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children
BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children
May 26, 2025
08:33 AM EDT, 05/14/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Wednesday that the US Food and Drug Administration has accepted and granted priority review to its new drug application for Orladeyo, or berotralstat, to treat hereditary angioedema in children 2 to 11 years old. The company said the FDA has set a target action date of Sept....
Copyright 2023-2026 - www.financetom.com All Rights Reserved